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REVIEW
Abstract: Oral opioids are the treatment of choice for chronic cancer pain. Morphine is the
strong opioid of choice for the treatment of moderate to severe cancer pain according to
guidelines from the World Health Organization (WHO). This recommendation by the WHO
was derived from availability, familiarity to clinicians, established effectiveness, simplicity
of administration, and relative inexpensive cost. It was not based on proven therapeutic
superiority over other options. Patients who experience inadequate pain relief or intolerable
side effects with one opioid may often be successfully treated with another agent or with the
same agent administered by a different route. Opioid rotation, or switching to an alternative
opioid, helps some patients achieve better pain control with fewer associated adverse effects.
Oxycodone is a µ-opioid receptor specific ligand, with clear agonist properties. It is an active
potent opioid, which is in part a κ-receptor agonist. Like morphine and other pure agonists,
there is no known ceiling to the analgesic effects of oxycodone. The active metabolites of
oxycodone (eg, oxymorphone) could be important in oxycodone-mediated analgesia. The
main pharmacokinetic difference between oxycodone and morphine is in oral bioavailability.
The bioavailability of oxycodone is >60% and the bioavailability of morphine is 20%.
Controlled-release oxycodone is absorbed in a bi-exponential fashion. There is a rapid phase
with a mean half-life of 37 min, accounting for 38% of the dose, and a slow phase with a half-
life of 6.2 h, which accounts for the residual 62%. Oxycodone elimination is impaired by
renal failure because there are both an increased volume of distribution and reduced clearance.
A lot of studies prove that the efficacy of controlled-release oxycodone in cancer-pain control
is at least the same as morphine, immediate-release oxycodone and hydromorphone. Its toxicity
profile seems better than that of morphine. There are actually several illustrations of a lower
incidence of side-effects in the central nervous system. It is therefore possible to conclude
that oxycodone represents a valid alternative to morphine in the management of moderate to
severe cancer pain, also as first-line treatment.
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Introduction
Oral opioids are the treatment of choice for chronic cancer pain (Levy 1996).
Morphine is the major opioid of choice for the treatment of moderate to severe cancer
pain according to guidelines from the World Health Organization (WHO). This
recommendation was based upon physicians’ familiarity with the molecule,
established effectiveness, simplicity of administration, and the general availability
of drug and its relatively inexpensive cost. It was not based on proven therapeutic
superiority over other options (Riley et al 2006).
Recently, the Research Network of the European Association for Palliative Care
(EAPC) performed a survey of 3030 cancer patients from 143 palliative-care centers
in 21 European countries. Patients were treated with analgesics corresponding to the
WHO pain ladder steps I (n=855), II (n=509), and III (n=1589). The investigators
assessed 32% of the patients as having moderate or severe pain. In general there
were small differences in pain intensities among different countries. Morphine was
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the most frequently used opioid for moderate to severe pain
(oral normal release morphine: 21%; oral sustained-release
morphine: 19%; intravenous [IV] or subcutaneous [SC]
morphine: 10%). Other opioids for moderate to severe pain
were transdermal fentanyl (14%), oxycodone (4%),
methadone (2%), diamorphine (2%), and hydromorphone
(1%) (Klepstad et al 2005).
Patients who experience inadequate pain relief or
intolerable side effects with one opioid may often be
successfully treated with another agent or with the same
agent administered by a different route (Ripamonti and
Dickerson 2001). Opioid rotation, or switching to an
alternative opioid, helps some patients achieve better pain
control with fewer associated adverse effects (Mercadante
1999). The pharmacological mechanism underlying this
phenomenon involves the diverse and combined effects of
agonist binding to the three opioid receptors (µ, κ, δ),
incomplete cross-tolerance, the diverse genetic background
of patients including allelic variations in the opioid receptors
themselves, as well as differences in drug clearance
mechanisms (Knapp et al 1989; Gaveriaux-Ruff and Kieffer
1999).
A prospective study was performed in the Department
of Palliative Care of the Royal Marsden National Hospital
Service Trust in London. In this trial 74% (138/186) of the
patients treated with morphine had a good response. Twenty-
five percent (47/186) did not respond to morphine. These
non-responders were switched to alternative opioids.
Furthermore, of the 186 patients, 37 achieved a successful
outcome when switched to oxycodone and an additional 4
were well controlled when switched to more than one
alternative opioid. Overall, successful pain control with
minimal side effects was achieved in 96% of patients. (Riley
et al 2006)
Pharmacokinetic and
pharmacodynamic
Oxycodone was derived from thebaine in 1916 (Gaveriaux-
Ruff and Kieffer 1999). It was introduced into clinical
practice in Germany in 1917 (Falk 1917). Oxycodone has a
liposolubility similar to morphine, and both are significantly
less lipid soluble than fentanyl (Poyhia et al 1993; Poyhia
and Seppala 1994).
Oxycodone is a µ-opioid receptor specific ligand, with
clear agonist properties. The Ki (nM) of oxycodone for the
µ-opioid receptor is 18±4 compared with 958±499 for
the δ-opioid receptor and 677±326 for the κ-opioid
receptor. The µ-opioid receptor binding affinity of
oxycodone is, however, less than that of morphine or
methadone. Oxymorphone, the active metabolite of
oxycodone, has a significantly higher µ-opioid receptor
binding affinity (Kalso 2005). The active metabolites of
oxycodone (eg, oxymorphone) could be important in
oxycodone-mediated analgesia. Studies using Dark Aguti
rats that are deficient in the enzyme CYP2D1, which is
required to O-demethylate oxycodone in rat, and various
opioid receptor antagonists have suggested that the
antinociceptive effects of oxycodone could be κ-opioid
receptor-mediated (Ross and Smith).
The metabolism of oxycodone in humans is still poorly
characterized. The main known metabolic pathways of
oxycodone are through O-demethylation to oxymorphone
and via N-demethylation to noroxycodone. Noroxycodone
concentrations in plasma and urine have been significantly
higher after oral than after intramuscular administration,
suggesting a prominent role of N-demethylation in the first-
pass metabolism of oxycodone. The conversion of
oxycodone to oxymorphone, as well as the conversion of
noroxycodone to noroxymorphone are catalyzed by the liver
OXYCODONE NOROXYCODONE 
CYP450 3A4 
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enzyme cytochrome P4502D6 (CYP2D6) (Figure 1) (Kress
2005)
This enzyme has two phenotypes in the white population:
5%–10% are poor metabolizers with diminished CYP2D6
activity. Most of oxycodone and noroxycodone is excreted
in the urine as the free (unconjugated) form, whereas
oxymorphone is mainly excreted in the conjugated form
(Kalso 2005). Gender, but not age, influences oxycodone
elimination: women eliminate oxycodone 25% more slowly
than men (Kaiko et al 1996).
The main pharmacokinetic difference between
oxycodone and morphine is in the oral bioavailability. The
bioavailability of oxycodone is >60% and the bioavailability
of morphine is 20% (Hoskin et al 1989).
Unlike normal release (NR) oxycodone, controlled-
release (CR) oxycodone is absorbed in a bi-exponential
fashion. There is a rapid phase with a mean half-life of
37min, accounting for 38% of the dose, and a slow phase
with a half-life of 6.2 h, which accounts for the residual 62%
(Mandema et al 1996).
Oxycodone elimination is impaired by renal failure
because there is both an increased volume of distribution
and a reduced clearance. Delayed clearance results in lower
concentrations of oxycodone and noroxycodone and
reduced elimination of free unconjugated oxymorphone
(Kirvela et al 1996).
The mean elimination half-life of oxycodone in end-
stage liver disease is 13.9 h (range 4.6–24.4 h). After liver
transplant it returns to 3.4 h (range 2.6–5.1 h) (Tallgren et al
1997). Therefore, care must be exercised when oxycodone
is used in cirrhosis or end-stage liver disease, and it is
necessary either to reduce the dose or extend dosage
intervals (Davis et al 2003).
Efficacy and safety in cancer pain
Oxycodone is mainly used as controlled-release tablets for
chronic pain. The immediate-release solution and tablets
are used for acute pain or for breakthrough pain. Parenteral
oxycodone is a good alternative when opioids cannot be
administered orally (Kalso 2005). Controlled-release
oxycodone is marketed as a twice-daily oral opioid for the
control of moderate-to-severe pain and has become one of
the most frequently prescribed opioids in the US (Davis et
al 2003).
The first controlled studies of oxycodone in cancer pain
were performed by Beaver and colleagues (1978a, 1978b).
These studies indicated that oxycodone could be a useful
oral analgesic as it had a higher oral bioavailability than
morphine. The first repeated-dose, cross-over studies
comparing IV patient-controlled analgesia (PCA) and oral
solutions of oxycodone and morphine were performed by
Kalso and Vainio (1990) and Kalso et al (1990). These
studies suggested that the oral bioavailability as calculated
from the daily consumption of each drug was 0.70 for
oxycodone and 0.31 for morphine. The daily oral dose of
oxycodone solution was suggested to be about 67% of the
morphine solution (2005). Controlled-release formulations
of both oxycodone and morphine have made a major
difference in the ease and simplicity of providing stable
opioid analgesia in cancer pain. Both CR oxycodone and
CR morphine provide, at proper doses, pain relief for 12 h.
The onset of analgesia is faster with CR oxycodone.
Four studies demonstrated that CR oxycodone every 12 h
is as effective as NR oxycodone in moderate to severe cancer
pain (Kaplan et al 1998; Parris et al 1998; Salzman et al
1999; Stamburgh et al 2001). Parris et al (1998) compared
the effectiveness and safety of CR oxycodone tablets with
immediate-release (IR) oxycodone in patients with chronic
cancer pain. With this aim, a multicenter, randomized,
double-blind, parallel-group study was performed in 111
patients with cancer pain. Patients received CR oxycodone
tablets every 12 h or IR oxycodone four times daily for 5
days. There was no significant difference between
treatment groups with regard to the incidence of adverse
events.This study demonstrates that cancer pain patients
can be equally well treated with CR oxycodone
administered every 12 h or IR oxycodone four times daily
at the same total daily dose. CR oxycodone offers the
benefits of twice daily dosing.
Kaplan et al (1998) randomized cancer patients who
required therapy for moderate to severe pain to CR
oxycodone every 12 h (n=81) or IR oxycodone four times
daily (n=83) for 5 days. Pain intensity remained slight during
the study, with mean oxycodone doses of 114 mg/d (range,
20 mg/d to 400 mg/d) for CR and 127 mg/d (range, 40 mg/d
to 640 mg/d) for IR. Acceptability of therapy was fair to
good with both treatments. Fewer adverse events were
reported with CR (109) than with IR (186) oxycodone
(p=0.006).
Salzman et al (1999) randomized 48 patients with cancer
pain to open-label titration with either CR or IR oxycodone
for a period of up to 21 days. Results of this study showed
no difference between CR and IR oxycodone with respect
to both the percentage of patients achieving stable pain
control, the time to achieve stable pain control, and the
degree of pain control achieved.Therapeutics and Clinical Risk Management 2006:2(3) 232
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Stambaugh et al (2001) randomized thirty patients with
cancer pain to receive CR oxycodone or IR oxycodone for
3 to 7 days followed by crossover at the same daily doses.
Following repeat dosing under double-blind conditions, oral
CR oxycodone administered every 12 h provided analgesia
comparable to IR oxycodone given four times daily. Adverse
events were similar for both medications.
Three studies have compared the CR formulations of
both oxycodone and morphine in cancer patients. In a
randomized, double-blind, cross-over trial, CR oxycodone
and morphine were administered to 45 adult patients with
stable pain for 3–6 days after open-label titration. In this
study, both CR oxycodone and CR morphine provided
adequate, stable analgesia, as most of the patients reported
their pain as ‘slight’ or ‘none’ at the end of the stable phases.
If the results of the two periods were combined, the patients
consumed significantly more escape doses and the mean
pain intensities were significantly higher with respect to CR
morphine compared with CR oxycodone (Heiskanen and
Kalso 1997).
In another study, 100 patients with cancer pain were
randomized to double-blind treatment with CR oxycodone
or CR morphine every 12 h for up to 12 days. Stable
analgesia was achieved in 83% of CR oxycodone and 81%
of CR morphine patients in 2 days (median). Following
titration to stabilize pain control, both drugs were also
comparably effective in reducing pain intensity from
baseline (Mucci-LoRusso et al 1998). In the third study, 32
patients with cancer pain who had achieved stable analgesia
on oral opioids were randomized to either CR oxycodone
or CR morphine for 7 days and then switched to the alternate
drug for another 7 days. Pain intensity was measured through
both a 100-mm visual analog scale (VAS) and a 5-term (0–4)
categorical scale (CAT). Both pain assessments were
comparable for the two drugs; mean VAS scores were 23±21
and 24±20, and CAT scores were 1.2±0.8 and 1.3±0.7 for CR
oxycodone and CR morphine, respectively (Bruera et al 1998).
With regard to the above trials, crossover designs were
used in two (Heiskanen and Kalso 1997; Bruera et al 1998),
whereas one was a parallel group study (Mucci-LoRusso et
al 1998). A total of 177 patients were included in these
studies and 73% completed the study protocol. All of the
studies suggest that both CR oxycodone and CR morphine
provide adequate analgesia in moderate to severe cancer
pain. The equianalgesic daily dose ratios of
oxycodone:morphine vary from 3:4 to 1:2. The mean daily
doses utilized were: CR oxycodone 148±18 mg (Heiskanen
et al 2000), 101 mg (40–360 mg) (Mucci-LoRusso et al
1998), 93±114 mg (Bruera et al 1998), and for CR morphine
204±24 mg (Heiskanen et al 2000), 140 mg (60–300 mg)
(Mucci-LoRusso et al 1998), and 145±204 mg (Bruera et al
1998).
The adverse effects reported by the patients were typical
opioid adverse effects, with no major differences between
the groups. Fewer hallucinations were reported with
oxycodone, as well as less nausea and pruritus, compared
with morphine (Mucci-LoRusso et al 1998) (Table 1) .
In addition to these data, a prospective trial by Maddocks
et al demonstrated that statistically significant improvements
in mental state as well as nausea and vomiting occurred
following a change from morphine to oxycodone (Maddocks
et al 1996).
Hagen and Babul (1997) randomized 44 patients with
stable cancer pain to receive CR oxycodone or CR
hydromorphone, each given every 12 h for 7 days, in a
double-blind crossover study. In this study there were no
significant differences between treatments in overall Visual
Analogue Scale (VAS) pain intensity (VAS 28±4 mm vs
31±4 mm), categorical pain intensity (1.4±0.1 vs 1.5±0.1),
daily rescue analgesic consumption (1.4±0.3 vs 1.6±0.3),
sedation scores (24±4 mm vs 18±3 mm), nausea scores
(15±3 mm vs 13±3 mm), or patient preference. Two patients
experienced hallucinations on CR hydromorphone, whereas
none of the patients suffered such side effects while receiving
CR oxycodone.
The above-described studies lasted for about a week in
each treatment arm. The long-term administration of CR
oxycodone was studied by Citron et al (1998). A total of 87
patients were included and 51% of the patients completed
the 3-month study. A significant but modest increase in the
total daily CR oxycodone dose was observed. However, the
percentage of patients reporting common opioid-related
Table 1 Incidence of adverse effects (Mucci-LoRusso et al
1998)
CR Oxycodone CR Morphine
(n=48) (n=52)
nn
Constipation 10 10
Drowsiness 7 10
Nausea 6 8
Vomiting 6 5
Vertigo 4 7
Pruritis 4 5
Dry mouth 1 7
Hallucinations 0 2
Abbreviations: CR, controlled release.Therapeutics and Clinical Risk Management 2006:2(3) 233
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adverse effects decreased over the course of the study (Kalso
2005).
Lauretti (2003) reported opioid synergy in chronic
cancer-related pain. Briefly, 22 patients received CR
morphine and CR oxycodone in a crossover design
involving two sequential 14-day treatment periods with IR
morphine available for breakthrough pain. The requirement
for breakthrough IR morphine was 38% higher in patients
receiving CR morphine than in patients receiving CR
oxycodone, suggesting that a synergistic analgesic
interaction took place when morphine was administered to
patients receiving CR oxycodone (Lauretti et al 2003)
(Figure 2).
Conclusions
In summary, oxycodone is a semisynthetic opioid analgesic
with a high oral-to-parenteral bioavailability and a 2-fold
greater oral potency than oral morphine. It is a µ-agonist
but its antinociceptive effects may also be κ-opioid receptor-
mediated Like morphine and other pure agonists, there is
no known ceiling to the analgesic effects of oxycodone. The
pharmacokinetics are altered by gender, less by age, and
significantly by impaired renal and hepatic function. CR
oxycodone exhibits bi-exponential pharmacokinetics and
less variable absorption than controlled-release morphine.
The equianalgesic daily dose ratios of oxycodone to
morphine vary from 3:4 to 1:2.
CR oxycodone combines the effectiveness and safety
of oral oxycodone with the convenience of dosing every
12 h. The delivery system used in the CR oxycodone tablet
matrix consists of two hydrophobic polymers, finely
balanced to ensure the measured release of oxycodone. The
properties of the matrix impart a bi-phasic absorption with
onset of action within 1 h in most patients, followed by a
more protracted phase that maintains effective blood
concentrations of oxycodone over a 12 h period.
All the above-mentioned studies confirm that the efficacy
of CR oxycodone in cancer-pain is at least the same as
morphine, IR oxycodone, and hydromorphone. Its
tolerability profile seems to be better than that of morphine
and indeed there are several illustrations of a lower incidence
of side-effects in the central nervous system. Further studies
are necessary to clarify the possible synergistic action that
oxycodone may exhibit when administered concurrently
with morphine. It is therefore possible to conclude that
oxycodone represents a valid first line alternative to
morphine in the management of moderate to severe cancer
pain.
Figure 2 Use of rescue medication. Average daily number of rescue doses of morphine (10 mg) administered (Lauretti et al 2003).
Abbreviations: CR, controlled release.
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